Unlock Asia’s Biopharma Potential with Scrip Asia 100
eBook
Commercial
Asia Pacific is rewriting the global biopharma narrative, and Scrip Asia 100 brings you unprecedented access to the region’s evolving landscape. Your competitors in financial services know that timely intelligence is essential for identifying investment opportunities and managing risk. This year’s report reveals how China’s meteoric growth as an R&D powerhouse is transforming dealmaking and licensing, rapidly outpacing the US and capturing over a third of global new active substance launches.
Our comprehensive analysis delves into the major cross-border deals, including headline-making alliances such as the $12bn GSK-Hengrui partnership, and the rise of South Korea and India as innovation hubs. Whether you’re seeking to understand the impact of shifting US policies on Indian generics, track Japan’s private equity activity, or pinpoint where financial capital is catalysing pharma transformation, Scrip Asia 100 is your gateway to actionable intelligence.
- Discover the fastest-growing R&D markets in Asia
- Evaluate the deal flow and investment trends shaping pharma and biotech
- Identify opportunities for M&A, partnerships, and asset licensing
- Gain expert insights into the regulatory and policy shifts affecting your portfolio
Backed by regional expertise and robust data, Scrip Asia 100 equips financial services leaders with the knowledge to navigate complexity and seize emerging opportunities. Tap into the report now to inform your next strategic move and enhance your competitive edge in the global biopharma sector.
Download your copy of Scrip Asia 100
